8-K: Alpha Teknova Reports 5% Revenue Increase in Q1 2025, Reaffirms Full-Year Guidance

Alpha Teknova announces a 5% increase in first quarter revenue to $9.8 million and reaffirms its 2025 revenue guidance of $39-42 million.

Summary

• Alpha Teknova reported its financial results for the first quarter ended March 31, 2025.
• Total revenue for Q1 2025 was $9.8 million, a 5% increase compared to $9.3 million in Q1 2024.
• Lab Essentials revenue increased by 12% to $8.1 million, while Clinical Solutions revenue decreased by 32% to $1.2 million.
• Gross profit increased to $3.0 million, with a gross margin of 30.7% compared to 23.8% in the prior year.
• Operating expenses decreased to $8.0 million, primarily due to lower stock-based compensation and reduced spending.
• Net loss improved to $4.6 million, or negative $0.09 per diluted share, compared to $8.1 million, or negative $0.20 per diluted share, in Q1 2024.
• Adjusted EBITDA was negative $2.5 million, an improvement from negative $3.8 million in the same quarter last year.
• Free cash outflow was negative $4.3 million, compared to negative $6.7 million in the first quarter of 2024.
• The company reaffirms its 2025 revenue guidance of $39 million to $42 million and anticipates free cash outflow of less than $12 million.
• Teknova entered into a collaboration with Pluristyx, Inc. to expand access to their novel PluriFreezeTM cryopreservation system.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results and reaffirmed guidance, although the company is still operating at a loss. The collaboration with Pluristyx is also a positive development.

Positives

• Total revenue increased by 5% to $9.8 million in Q1 2025.
• Lab Essentials revenue grew by 12% to $8.1 million.
• Gross margin improved to 30.7% from 23.8% in the prior year.
• Net loss decreased from $8.1 million to $4.6 million.
• Adjusted EBITDA improved from negative $3.8 million to negative $2.5 million.
• Free cash outflow improved from negative $6.7 million to negative $4.3 million.
• The company reaffirmed its 2025 revenue guidance of $39 million to $42 million.
• Teknova is now the exclusive manufacturer and distributor of PluriFreezeTM cryopreservation system in the United States and Canada.

Negatives

• Clinical Solutions revenue decreased by 32% to $1.2 million in Q1 2025.
• The company still reported a net loss of $4.6 million for the quarter.
• Adjusted EBITDA remains negative at $2.5 million.
• Free cash outflow is still negative at $4.3 million.

Risks

• The company acknowledges the uncertain macroenvironment.
• Reliance on a limited number of customers for a high percentage of revenue is a risk.
• Global economic and marketplace uncertainties, including conflicts in Ukraine and the Middle East, could impact the company.
• Potential delays or pausing of customer orders could affect revenue.
• The company's supply chain, sourcing, manufacturing, and warehousing could be impacted by various factors.

Future Outlook

Teknova reiterates its fiscal 2025 outlook for revenue and free cash outflow, anticipating total revenue of $39 million to $42 million and free cash outflow of less than $12 million.

Management Comments

• Stephen Gunstream, President and Chief Executive Officer, stated that the company delivered strong financial and operational results in the first quarter.
• He attributed the organic growth to the criticality of their product portfolio and diversity of their customer base.
• Matt Lowell, Chief Financial Officer, highlighted the strong financial results, including 5% revenue growth and significant improvements in adjusted EBITDA and free cash outflow.
• Matt Lowell believes the company is well positioned to maintain its momentum and reiterated the 2025 revenue guidance and free cash outflow expectations.

Industry Context

Teknova's focus on critical reagents for the life sciences industry positions it to benefit from the growth in novel therapies, vaccines, and molecular diagnostics. The collaboration with Pluristyx, Inc. strengthens Teknova's cell therapy product portfolio, aligning with the increasing demand for cell and gene therapies.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Teknova's specific product mix and target markets.
• However, companies like Thermo Fisher Scientific, Danaher, and Merck KGaA are major players in the life sciences reagents market.
• These companies often have higher revenue and profitability due to their scale and diversified product offerings.
• Teknova's growth rate and margin improvements suggest it is performing well relative to smaller, specialized reagent providers.
• The company's focus on customizable solutions and fast turnaround times could provide a competitive advantage.

Stakeholder Impact

• Shareholders will likely view the improved financial results and reaffirmed guidance positively.
• Employees may be encouraged by the company's growth and improved financial performance.
• Customers can expect continued access to critical reagents and solutions.
• Suppliers may benefit from increased demand for Teknova's products.
• Creditors may view the improved financial performance as a positive sign of the company's ability to meet its obligations.

Next Steps

• Teknova will attend the Sidoti Micro Cap Conference on May 21, 2025.
• Teknova will attend the William Blair 45th Annual Growth Stock Conference on June 4, 2025.
• Teknova will attend the Jefferies 2025 Global Healthcare Conference on June 5, 2025.

Key Dates

Keywords

Teknova, financial results, revenue, Q1 2025, guidance, reagents, PluriFreeze, cryopreservation, EBITDA, cash flow